Ronald J Hogg: Influence Statistics

Ronald J Hogg

Ronald J Hogg

Scott & White Clinic, Temple, TX, United States Of America | Baylor Scott and White Healthcare, Temple, TX | Scott & White Clinic, Temple, Texas, United States of America | ...


Download all Influence Scores

Ronald J Hogg: Expert Impact

Concepts for which Ronald J Hogg has direct influence: Iga nephropathy , Serum levels , Nephrotic syndrome , Binding protein , Chronic kidney disease , Chronic renal failure , Multicenter studies .

Ronald J Hogg: KOL impact

Concepts related to the work of other authors for which for which Ronald J Hogg has influence: Chronic kidney disease , Renal function , Nephrotic syndrome , Iga nephropathy , Heart failure , Glomerular filtration , Blood pressure .

KOL Resume for Ronald J Hogg

Year
2015

Scott & White Clinic, Temple, TX, United States Of America

2013

Scott & White Clinic, Temple, Texas, United States of America

2012

Scott & White Clinic, Temple, TX, USA

Due to the number of contributing authors, the affiliations are provided in the Supplemental Material

2011

Department of Pediatrics, The Children's Hospital at Scott White, Temple, Texas, USA

2010

The Children’s Hospital at Scott White Medical Center, Department of Pediatrics, Temple, Texas, USA

2009

Department of Pediatrics, The Children’s Hospital, Scott and White Memorial Hospital and Clinic, and the Scott, Sherwood and Brindley Foundation and Texas A&M College of Medicine, 2401 South 31st Street, Temple, Texas 76508 USA

2008

The Children's Hospital at Scott & White, Temple, Texas

2007

St. Joseph’s Hospital & Medical Center, 222 W. Thomas Rd., Suite 410, 85013, Phoenix, AZ, USA

2006

*St. Joseph’s Hospital and Medical Center, Phoenix, Arizona; †Department of Clinical Research, Medical City Dallas Hospital, Dallas, Texas; and ‡A.T. Still University, Mesa, Arizona

Medical City Dallas Hospital, Dallas, TX

2005

Division of Pediatric Nephrology St. Joseph's Hospital and Medical Center, 2346 North Central Avenue, Phoenix, AZ 85004, USA

2004

Department of Pediatrics, Medical City Dallas Hospital, Dallas, TX, USA

From the Duke Clinical Research Institute (J.S.L., K.B., R.K., R.M.C.), Duke University Medical Center, Durham, NC; Impact Clinical Trials (L.H.), Los Angeles, Calif; University of Texas at Houston Medical School (R.P.), Houston; Medical City Dallas Hospital (R.H.), Tex; Northwest Pediatric Kidney Specialists (R.D.J.), Portland, Ore; Children’s Hospital of Pittsburgh (P.K.), Pa; Pediatric Cardiology (C.M.C), PSC, Lexington, Ky; Children’s Hospital of Michigan (T.K.M.), Detroit; Smolensk State Medical Academy (L.Z., L.K.), Russia; Western Galilee Hospital (I.W.), Nahariya, Israel; and Bristol-Myers Squibb Company (D.D.), Princeton, NJ.

2003

North Texas Hospital for Children, Dallas, Texas, USA

Department of Pediatrics, Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Hospital for Sick Children, Toronto, Ontario, Canada; the Department of Pediatrics, Columbia Hospital at Medical City, Dallas, Texas; and Merck & Co, Inc, Blue Bell, Pennsylvania

2002

Department of Pediatrics, Columbia Hospital at Medical City, Dallas Texas, USA

University of Washington and Children's Hospital, Seattle, WA; University of Texas Southwestern Medical Center; Medical City Dallas Hospital, Dallas; Baylor College of Medicine, Houston, TX; and Merck Research Laboratories, West Point, PA.

Instituto Nacional de Salud Nino, Lima, Peru

Luis Calvo Mackenna Hospital, Santiago, Chile

2001

Division of Pediatric Nephrology, North Texas Hospital for Children at Medical City Dallas Hospital, Dallas, TX, USA, US

North Texas Hospital for Children, Medical City Dallas Hospital, Dallas, Texas

2000

Merck Research Labs, West Point, PA, USA

From North Texas Hospital for Children at Medical City Dallas, Dallas, Texas;

1997

Stanford University Medical School, Stanford, California

Diagnostic Systems Laboratories, Inc., Webster, Texas

University of Washington, Seattle, Washington

1996

Department of Pediatrics, Medical City Dallas Hospital, TX 75230-2518, USA.

1995

Southwest Pediatric Nephrology Study Group, Baylor University Medical Center, Dallas, Tex., USA.

1994

SPNSG Central Office, Baylor University Medical Center, 3500 Gaston Avenue, 75246, Dallas, TX, USA

1993

Southwest Pediatric Nephrology Study Group, Department of Pediatrics, Baylor University Medical Center, 3500 Gaston Avenue, 75246, Dallas, TX, USA

University of California, San Francisco, San Francisco, California

1992

Department of Pediatrics, Baylor University Medical Center, 3500 Gaston Avenue, 75246, Dallas, TX

1991

Southwest Pediatric Nephrology Study Group, Baylor University Medical Center, Dallas, Texas, USA

1990

Baylor University Medical Center, Dallas, Texas, USA

1988

From the Department of Pediatrics, Baylor University Medical Center, Dallas.

Baylor University Medical Center, Dallas, TX 75246.

1987

Department of Pediatrics, University of Texas Health Science Center and Baylor University Medical Center, Dallas, Texas, USA

1985

Southwest Pediatric Nephrology Study Group Central Office, Department of Pediatrics, University of Texas Health Science Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75235, USA

1983

Departments of Pediatrics and Pediatric Surgery, University of Texas Health Science Center at Dallas.

1981

Department of Pediatrics, The University of Texas Health Science Center at Dallas, Dallas

Prominent publications by Ronald J Hogg

KOL-Index: 12351 . Anthropometric measurements and circulating growth factors were studied serially in 44 prepubertal children with growth failure and chronic renal failure (GFR = 10 to 40 ml/min/1.73 m2) who were randomized to receive either recombinant human growth hormone (rhGH; N = 30) or no treatment (N = 14). RhGH was given as Nutropin, 0.05 mg/kg/day, and the studies were carried out at baseline and ...
Known for Growth Factor | Chronic Renal | Serum Levels | 12 Months
KOL-Index: 10293 . INTRODUCTION: Conflicting findings in both interventional and observational studies have resulted in a lack of consensus on the benefits of ω3 fatty acids in reducing disease risk. This may be due to individual variability in response. We used a multi-platform lipidomic approach to investigate both the consistent and inconsistent responses of individuals comprehensively to a defined ω3 ...
Known for Fatty Acids | Lipidomic Profiles | Epa Dha | Individual Variability
KOL-Index: 10278 . Continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD) have become acceptable methods of treatment for children with endstage renal disease (ESRD). In this study we have compared the effectiveness of these two modalities of prolonged dwell peritoneal dialysis in 82 children treated at home with CAPD and/or CCPD for a mean of 10.2 months. Forty ...
Known for Continuous Ambulatory | Peritoneal Dialysis | Capd Ccpd | Growth Children
KOL-Index: 9773 . Forty children with hypertension between the age of 2 months and 15 years received 0.07 to 0.14 mg/kg of enalapril as a single daily dose. Enalapril was administered orally as a novel extemporaneous suspension in children younger than 6 years of age and as tablets in older children. First-dose and steady-state pharmacokinetics were estimated in children ages 1 to 24 months, 25 months to < ...
Known for Enalapril Children | 6 Years | Active Metabolite | Antihypertensive Agents
KOL-Index: 9543 . IgA nephropathy and Henoch-Schönlein purpura nephritis (HSPN) are related diseases characterized by deposits of IgA1-containing immune complexes in the renal mesangium. Adult patients with IgA nephropathy have aberrantly glycosylated IgA1 (galactose-deficient O-linked glycans) in the circulation and renal deposits. However, IgA1 glycosylation has not been studied in pediatric patients with ...
Known for Iga Nephropathy | Serum Levels | Schönlein Purpura | Pediatric Patients
KOL-Index: 9349 . Optimal therapy of patients with steroid-resistant primary focal segmental glomerulosclerosis (FSGS) remains controversial. This report describes the initial study design, baseline characteristics, and quality of life of patients enrolled in the FSGS Clinical Trial, a large multicenter randomized study of this glomerulopathy comparing a 12-month regimen of cyclosporine to the combination ...
Known for Focal Segmental | Quality Life | Patients Fsgs | Immunosuppressive Agents
KOL-Index: 8716 . We undertook a preliminary study to determine if a clinical trial was feasible that would compare the effect of a low protein vs a control formula on GFR and growth in infants with congenital renal insufficiency (CIo < 55 ml/min/1.73 m2). In this report from the Infant Diet Protein Study, we describe validation of a method using the plasma clearance of iothalamate (CIo) as an estimate of ...
Known for Gfr Cio | Plasma Clearance | Low Protein | Clinical Trial
KOL-Index: 8678 . BACKGROUND: Previous randomized controlled trials evaluating the efficacy of mycophenolate mofetil (MMF) in patients with immunoglobulin A nephropathy (IgAN) have produced varying results. STUDY DESIGN: Double-blind placebo-controlled randomized controlled trial. SETTING & PARTICIPANTS: 52 children, adolescents, and adults with biopsy-proven IgAN in 30 centers in the United States and ...
Known for Mycophenolate Mofetil | Iga Nephropathy | Randomized Controlled | 95 Mmf
KOL-Index: 8625 . Clinicopathologic correlations were examined in 75 children with focal segmental glomerulosclerosis (FSGS) associated with idiopathic nephrotic syndrome. The biopsy specimens of all patients were examined by electron microscopy (69 patients) or immunofluorescence microscopy (67 patients) in addition to light microscopy. Fifty-three patients (group A) had FSGS diagnosed on their first ...
Known for Focal Segmental | Children Fsgs | Chronic Kidney | Idiopathic Nephrotic
KOL-Index: 8208 . OBJECTIVES: Evaluation of the efficacy and safety of amlodipine in hypertensive children. STUDY DESIGN: A randomized, double blinded, placebo-controlled, parallel-group, dose-ranging study was conducted at 49 centers in North and South America. The primary end point was the effect of amlodipine on systolic blood pressure (BP); secondary end points included the effect of amlodipine on ...
Known for Hypertensive Children | Safety Amlodipine | Primary Hypertension | Systolic Diastolic
KOL-Index: 8197 . PURPOSE: To determine the incidence of avascular necrosis (AVN) of the femoral head in children with chronic renal failure. MATERIALS AND METHODS: Pelvic radiographs in 205 children (age range, 6 months to 16 years; mean age, 6 years +/- 3.5 [SD]) with chronic renal failure were reviewed. Serial radiographs were obtained every 6 months for 1-7 years (mean, 3 years +/- 2) to assess the ...
Known for Femoral Head | Renal Disease | Avascular Necrosis | Children Chronic

Key People For Iga Nephropathy

Top KOLs in the world
#1
Bruce A Julian
iga nephropathy african americans renal transplantation
#2
Yasuhiko Tomino
iga nephropathy diabetic rats chronic kidney disease
#3
John Feehally
iga nephropathy renal function acute kidney injury
#4
Rosanna Coppo
iga nephropathy glomerular disease oxford classification
#5
F Paolo Principal discussant: Schena
iga nephropathy renal damage growth factor
#6
Robert J Wyatt
iga nephropathy complement activation serum levels

Scott & White Clinic, Temple, TX, United States Of America | Baylor Scott and White Healthcare, Temple, TX | Scott & White Clinic, Temple, Texas, United States of America | Scott & White Clinic, Temple, TX, USA | Due to the number of contributing aut